Malaysia Genomic Diagnostics Market Report 2023 to 2030

Malaysia Genomic Diagnostics Market Analysis

$ 3999

Malaysia Genomic Diagnostics Market was valued at $52.49Mn in 2023 and is predicted to grow at a CAGR of 16.7% from 2023 to 2030, to $154.74Mn by 2030. The key drivers of this industry include the growing elderly population, rising incidence of chronic diseases, and advancements in genomic sequencing technologies. The industry is primarily dominated by Illumina, 23andMe, Myriad Genetics, and Amgen among others.

ID: IN10MYHS054 CATEGORY: Healthcare Services GEOGRAPHY: Malaysia AUTHOR: Sarita Yadav

Buy Now

Malaysia Genomic Diagnostics Market Executive Summary

Malaysia Genomic Diagnostics Market was valued at $52.49Mn in 2023 and is predicted to grow at a CAGR of 16.7% from 2023 to 2030, to $154.74Mn by 2030.

Genomic diagnostics is a rapidly evolving field that uses an individual's genetic information to diagnose diseases, assess predisposition to future health problems, and guide treatment plans by analyzing DNA or RNA for disease-linked variations. This includes karyotyping to examine chromosome abnormalities, targeted mutation analysis for specific disease-related genes, and next-generation sequencing (NGS) for a comprehensive genetic analysis. Applications encompass disease diagnosis, carrier testing for informed family planning, predictive testing for disease risk assessment, and pharmacogenomics for personalized medication treatments. The benefits of genomic diagnostics include early disease detection, personalized medicine, and improved disease management and prognosis.

About 8.1% of the adult population in Malaysia, or 1.7Mn people, have all three risk factors for diabetes, hypertension, and high cholesterol, the main non-communicable diseases. According to the National Health and Morbidity Survey (NHMS) 2019 by the Ministry of Health (MOH), the prevalence rate of diabetes in adults has increased in Malaysia from 13.4% in 2015 to 18.3% in 2019, with diabetes defined as having sugar levels 7.0 mmol/L or above.

Market is therefore driven by significant factors like the growing elderly population, rising incidence of chronic diseases, and advancements in genomic sequencing technologies. However, high costs, lack of skilled personnel, and regulatory hurdles restrict the growth and potential of the market.

A prominent player in this field is Illumina, which has partnered with AstraZeneca to leverage genomics and AI for faster drug development by identifying new therapeutic targets and biomarkers, 23andMe acquired Lemonaid Health to enhance its personalized healthcare offerings through telehealth and prescription drug delivery services based on genetic information. Other contributors include Myriad Genetics, and Amgen among others.

Malaysia Genomic Diagnostics Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Growing Elderly Population: Malaysia's rapidly aging population, projected to increase from 11.1% aged 60 and older in 2020 to 23.1% by 2050, is driving demand for advanced diagnostic tools like genomics to manage chronic diseases.

Rising Incidence of Chronic Diseases: The high burden of infectious diseases and rising chronic conditions such as diabetes (from 13.4% in 2015 to 18.3% in 2019), hypertension (30% of adults), and obesity (from 17.7% in 2015 to 19.7% in 2019) are increasing the need for precise diagnostics.

Advancements in Genomic Sequencing Technologies: Rapid advancements in DNA sequencing techniques and bioinformatics are making genomic diagnostics more accessible and affordable, enhancing healthcare in Malaysia.

Market Restraints

High Costs: The high expense of advanced molecular diagnostics and in vitro diagnostic devices challenges widespread adoption, particularly in resource-limited settings.

Lack of Skilled Personnel: A shortage of trained professionals in Malaysia hinders the interpretation of complex genomic data and the provision of genetic counseling to patients.

Regulatory Hurdles: Stringent premarket approval (PMA) and in vitro diagnostic (IVD) labeling requirements add significant time and expense to bringing new genomic tests to market.

Regulatory Landscape and Reimbursement Scenario

Malaysia's healthcare and life sciences sectors, including genomics, are regulated by the National Pharmaceutical Regulatory Agency (NPRA), which ensures the safety and efficacy of medical devices, drugs, and cosmetics. The NPRA is pivotal in approving new genomic tests and maintaining high standards in the healthcare industry.

Reimbursement for genomic diagnostics in Malaysia is multifaceted, involving the Ministry of Health (MOH) and private health insurance providers. The MOH, as the main healthcare provider, significantly influences reimbursement policies for genomic tests. Meanwhile, the expanding private health insurance sector offers varied coverage levels for these diagnostics, reflecting a growing recognition of their importance in personalized medicine.

Competitive Landscape

Key Players

Here are some of the major key players in the Malaysia Genomic Diagnostics

Illumina, Inc.
Myriad Genetics, Inc.
Amgen, Inc.
23andMe
Thermo Fisher Scientific
Becton, Dickinson and Company (BD)
Qiagen
Roche Diagnostics
Abbott Laboratories
Danaher Corporation

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Malaysia Genomic Diagnostics Market Segmentation

By Technology

Next Generation Sequencing
Array Technology
PCR-based Testing
FISH
Others

By Application

Ancestry & Ethnicity
Traits Screening
Genetic Disease Carrier Status
New Baby Screening
Health and Wellness-Predisposition/Risk/Tendency

By Product

Consumables
Equipment
Software & Services

By End-user

Hospitals & Clinics
Diagnostic Laboratories
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.